ALICIA HAINES: Open Payments
NPI 1396471678 · MINDEN, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$816 in 47 payments from 12 companies in 2025. Trend: 2023 $62 · 2024 $505 · 2025 $816
Food & beverage: $816
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $246 |
| Novo Nordisk Inc | 15 | $141 |
| PFIZER INC. | 5 | $101 |
| Astellas Pharma US Inc | 3 | $58 |
| GlaxoSmithKline, LLC. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Edwards Lifesciences Corporation | 1 | $40 |
| Lilly USA, LLC | 2 | $35 |
| Exact Sciences Corporation | 1 | $33 |
| MAYNE PHARMA COMMERCIAL LLC | 1 | $23 |
Products named: VRAYLAR, Ozempic, PREVNAR 20, Veozah, TRELEGY ELLIPTA, Rybelsus, UBRELVY, CAPLYTA.
Industry payments across NV — which companies pay providers there.
